These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer. Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555 [TBL] [Abstract][Full Text] [Related]
44. Surface modification of doxorubicin-loaded nanoparticles based on polydopamine with pH-sensitive property for tumor targeting therapy. Bi D; Zhao L; Yu R; Li H; Guo Y; Wang X; Han M Drug Deliv; 2018 Nov; 25(1):564-575. PubMed ID: 29457518 [TBL] [Abstract][Full Text] [Related]
45. Biotin decorated PLGA nanoparticles containing SN-38 designed for cancer therapy. Mehdizadeh M; Rouhani H; Sepehri N; Varshochian R; Ghahremani MH; Amini M; Gharghabi M; Ostad SN; Atyabi F; Baharian A; Dinarvand R Artif Cells Nanomed Biotechnol; 2017 May; 45(3):495-504. PubMed ID: 27137460 [TBL] [Abstract][Full Text] [Related]
46. Effects of poly(ethylene glycol) grafting density on the tumor targeting efficacy of nanoparticles with ligand modification. Zhang S; Tang C; Yin C Drug Deliv; 2015 Feb; 22(2):182-90. PubMed ID: 24215373 [TBL] [Abstract][Full Text] [Related]
47. Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy. Deng C; Jia M; Wei G; Tan T; Fu Y; Gao H; Sun X; Zhang Q; Gong T; Zhang Z Mol Pharm; 2017 Jan; 14(1):296-309. PubMed ID: 27936775 [TBL] [Abstract][Full Text] [Related]
48. A cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy. Wang ZQ; Liu K; Huo ZJ; Li XC; Wang M; Liu P; Pang B; Wang SJ J Nanobiotechnology; 2015 Oct; 13():63. PubMed ID: 26427800 [TBL] [Abstract][Full Text] [Related]
49. Enhanced uptake and transport of PLGA-modified nanoparticles in cervical cancer. Sims LB; Curtis LT; Frieboes HB; Steinbach-Rankins JM J Nanobiotechnology; 2016 Apr; 14():33. PubMed ID: 27102372 [TBL] [Abstract][Full Text] [Related]
50. Tunable conjugation densities of camptothecin on hyaluronic acid for tumor targeting and reduction-triggered release. Chen Z; He N; Chen M; Zhao L; Li X Acta Biomater; 2016 Oct; 43():195-207. PubMed ID: 27424081 [TBL] [Abstract][Full Text] [Related]
51. Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles. Xiao B; Zhang M; Viennois E; Zhang Y; Wei N; Baker MT; Jung Y; Merlin D Biomaterials; 2015 Apr; 48():147-60. PubMed ID: 25701040 [TBL] [Abstract][Full Text] [Related]
52. Synthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for pancreatic cancer. Dobiasch S; Szanyi S; Kjaev A; Werner J; Strauss A; Weis C; Grenacher L; Kapilov-Buchman K; Israel LL; Lellouche JP; Locatelli E; Franchini MC; Vandooren J; Opdenakker G; Felix K J Nanobiotechnology; 2016 Dec; 14(1):81. PubMed ID: 27993133 [TBL] [Abstract][Full Text] [Related]
53. Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation. Botella P; Abasolo I; Fernández Y; Muniesa C; Miranda S; Quesada M; Ruiz J; Schwartz S; Corma A J Control Release; 2011 Dec; 156(2):246-57. PubMed ID: 21756949 [TBL] [Abstract][Full Text] [Related]
54. In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy. Mosafer J; Abnous K; Tafaghodi M; Mokhtarzadeh A; Ramezani M Eur J Pharm Biopharm; 2017 Apr; 113():60-74. PubMed ID: 28012991 [TBL] [Abstract][Full Text] [Related]
55. Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin. Liu R; Wang Y; Li X; Bao W; Xia G; Chen W; Cheng J; Xu Y; Guo L; Chen B Drug Des Devel Ther; 2015; 9():2705-19. PubMed ID: 26045659 [TBL] [Abstract][Full Text] [Related]
56. Ultrasound-guided delivery of microRNA loaded nanoparticles into cancer. Wang TY; Choe JW; Pu K; Devulapally R; Bachawal S; Machtaler S; Chowdhury SM; Luong R; Tian L; Khuri-Yakub B; Rao J; Paulmurugan R; Willmann JK J Control Release; 2015 Apr; 203():99-108. PubMed ID: 25687306 [TBL] [Abstract][Full Text] [Related]
57. Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition. Jiang Y; Yang N; Zhang H; Sun B; Hou C; Ji C; Zheng J; Liu Y; Zuo P J Control Release; 2016 Jan; 221():26-36. PubMed ID: 26643616 [TBL] [Abstract][Full Text] [Related]
58. iRGD-decorated red shift emissive carbon nanodots for tumor targeting fluorescence imaging. Yang Y; Wang X; Liao G; Liu X; Chen Q; Li H; Lu L; Zhao P; Yu Z J Colloid Interface Sci; 2018 Jan; 509():515-521. PubMed ID: 28923749 [TBL] [Abstract][Full Text] [Related]
59. Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil. El-Hammadi MM; Delgado ÁV; Melguizo C; Prados JC; Arias JL Int J Pharm; 2017 Jan; 516(1-2):61-70. PubMed ID: 27825867 [TBL] [Abstract][Full Text] [Related]
60. Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38. Ebrahimnejad P; Dinarvand R; Jafari MR; Tabasi SA; Atyabi F Int J Pharm; 2011 Mar; 406(1-2):122-7. PubMed ID: 21185365 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]